Most cases of cervical cancer are linked to a few strains of the human papillomavirus (HPV). The pharmaceutical company Merck developed a vaccine (Gardasil) against these HPV strains. Worldwide clinical trials followed young women 16 to 26 years of age after vaccination or administration of a placebo for two to four years for signs of HPV-caused cervical cancer. Of 8464 women given Gardasil, none developed HPV-caused cervical cancer. In contrast, 56 of the 8477 women given a placebo did.1 Conduct the calculation steps to determine the plus four 99% confidence interval for the difference between the two population proportions (p1 - p2) of women developing HPV-caused cervical cancer. Let p1 represent the population proportion for the Gardasil patient population and p2 represent the population proportion for the placebo patient population. Find the plus four sample proportion p, of those who received Gardasil and developed cervical cancer. Provide your answer to five decimal places. P1 = Find the plus four sample proportion p2 of those who received the placebo and developed cervical cancer. Provide your answer to five decimal places. P2 =